Skip to main content
. 2025 Aug 22;11:253. doi: 10.1038/s41531-025-01107-8

Table 1.

Patients and healthy controls clinical characteristics

Characteristics TD subjects (n = 69) ET patients (n = 71) HC subjects (n = 80) P value
Age (year) 63.62 ± 6.66 65.31 ± 7.91 63.84 ± 5.16 0.271a
Gender (Male/Female) 37/32 32/39 37/43 0.545b
Education (year) 14.13 ± 10.51 13.61 ± 4.66 12.98 ± 5.30 0.381c
Age at onset (year) 54.61 ± 9.02 49.05 ± 12.84 - 0.007d**
Duration (year) 9.28 ± 7.16 16.41 ± 12.48 - <0.001d***
TETRAS - 30.43 ± 11.14 - -
FTMT - 49.62 ± 27.63 - -
UPDRS-III (med off) 45.75 ± 15.25 - - -
UPDRS-III (med on) 22.85 ± 12.91 - - -
MMSE 27.57 ± 1.46 26.96 ± 2.36 - 0.102d
MoCA 23.36 ± 3.04 21.38 ± 4.88 - 0.005d**
HAM-A 15.42 ± 9.20 10.42 ± 7.60 - 0.001d**
HAM-D 16.59 ± 9.91 11.35 ± 7.41 - 0.001d**
VHI 25.51 ± 22.09 7.62 ± 18.73 - <0.001d***

Values are presents as the mean ± standard deviation.

TD Tremor-dominant Parkinson’s disease, ET Essential tremor, HC healthy controls, TETRAS The Essential Tremor Rating Assessment Scale, FTMT Fahn Tolosa Marin Tremor Rating Scale, UPDRS-III the Unified Parkinson’s Disease Rating Scale part 3, MMSE Mini- Mental State Examination, MoCA Montreal Cognitive Assessment, HAM-A Hamilton Rating Scale for Anxiety, HAM-D Hamilton Rating Scale for Depression, VHI Voice Handicap Index.

aKruskal-Wallis test.

bChi-Squared test.

cANOVA test.

dTwo-sample t-test for ET and TD group.

**p < 0.01, ***p < 0.001.